Daniel DeOliveira, PhD

Vice President, Drug Substance Development and Manufacturing at Kailera Therapeutics

Speaker

Dr. Daniel B. DeOliveira has 20+ years contributing to Drug Discovery and Development primarily focused in the area of peptides and peptidomimetics. He has led drug discovery efforts focusing on rare diseases, oncology, immuno-oncology and nuclear medicine. Dr. DeOliveira's drug development experience includes leading GMP manufacture campaigns for personalized (autologous) clinical trials as well as classical large scale / multi-patient trials. His efforts have been instrumental in the FDA approval of Ecallantide (Kalbitor) and Setmelanotide (Imcivree). He has many publications and patents to his name and has been an invited speaker at numerous conferences. Dr. DeOliveira also holds Professional Management Professional (PMP) accreditation. He is currently Vice President of Drug Substance Manufacturing and Development at Kailera Therapeutics.